%0 Journal Article %A Inez Bronsveld %A François Vermeulen %A Dorotha Sands %A Teresinha Leal %A Anissa Leonard %A Paola Melotti %A Yasmin Yaakov %A Roel de Nooijer %A Kris De Boeck %A Isabelle Sermet %A Michael Wilschanski %A Peter G Middleton %A On behalf of the European Cystic Fibrosis Society – Diagnostic Network Working Group %T Influence of perfusate temperature on nasal potential difference %D 2012 %R 10.1183/09031936.00097712 %J European Respiratory Journal %P erj00977-2012 %X Nasal potential difference (NPD) quantifies the abnormal ion transport in cystic fibrosis (CF). It has gained acceptance as an outcome measure for investigation of new therapies.To quantify the effect of solution temperature on the NPD, we first examined the effect of switching from room temperature (RT: 20–25°C) to warmed solutions (W:32–37°C) and vice versa during each perfusion step. Secondly, standard protocols were repeated at both temperatures in the same subjects.Changing solution temperature did not alter NPD during perfusion with Ringers solution (<1 mV, p>0.1). During perfusion with zero-chloride solution, changing from RT to W tended to decrease absolute NPD (ie became less negative) by 0.9 mV(p>0.1); changing from W to RT increased NPD by 2.1 mV(p<0.05). During isoprenaline perfusion, changing from RT to W increased NPD by 1.5 mV(p<0.01), and from W to RT decreased PD by 1.4 mV(p<0.05).For full protocols at RT or W in the same subjects, mean values were similar (n=24). During W perfusion, group results for total chloride response had a larger standard deviation. As this increased variability will likely decrease the power of trials, this study suggests that room temperature solutions should be recommended for the measurement of nasal PD. %U https://erj.ersjournals.com/content/erj/early/2012/10/25/09031936.00097712.full.pdf